CND Life Sciences

CND Life Sciences is dedicated to supporting the care of patients suffering from neurodegenerative diseases and other conditions.  Operating a CLIA-certified laboratory in Phoenix, AZ, CND launched the Syn-One Test™ as the first commercially available test to detect, visualize, and quantify the presence of abnormal, phosphorylated alpha-synuclein in cutaneous nerve fibers.  The test serves as an objective diagnostic tool to aid in the confirmation of synucleinopathy in patients with suspected Parkinson’s disease (PD), dementia with Lewy body (DLB), multiple system atrophy (MSA), or pure autonomic failure (PAF). Through analysis of three small punch skin biopsies provided by a referring physician, CND offers a convenient, accurate, minimally invasive alternative to aid in the diagnosis of neurodegenerative diseases.  The company has research collaborations with multiple biopharmaceutical companies and is committed to advancing science in the field.